Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study

The Lancet Oncology

Volumn 10, Issue 10, 2009, Pages 950-956

  Grass, Sandra ^a   Preuss, Klaus Dieter ^a   Ahlgrimm, Manfred ^a   Fadle, Natalie ^a   Regitz, Evi ^a   Pfoehler, Claudia ^a   Murawski, Niels ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PARAPROTEIN; PARATARG 7; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC RISK; HUMAN; ISOELECTRIC FOCUSING; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PEDIGREE ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ADULT; AGED; BLOOD PROTEINS; CASE-CONTROL STUDIES; CHILD; FEMALE; GENES, DOMINANT; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; PARAPROTEINS; PEDIGREE; PHOSPHORYLATION;

EID: 70349403690     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70234-7     Document Type: Article

References (46)

1. Landgren O., Kyle R.A., Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113 (2009) 5412-5417
2. Lynch H.T., Ferrara K., Barlogie B., et al. Familial myeloma. N Engl J Med 359 (2008) 152-157
3. Landgren O., Kristinsson S.Y., Goldin L.R., et al. Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden. Blood 114 (2009) 791-795
4. Brown L.M., Gridley G., Check D., and Landgren O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111 (2008) 3388-3394
5. Landgren O., Gridley G., Turesson I., et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107 (2006) 904-906
6. Landgren O., and Weiss B.M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia (2009) 10.1038/leu.2009.134 published online July 9.
7. Soderberg K.C., Hagmar L., Schwartzbaum J., and Feychting M. Allergic conditions and risk of hematological malignancies in adults: a cohort study. BMC Public Health 4 (2004) 51
8. Jack H.M., Beck-Engeser G., Lee G., Wofsy D., and Wabl M. Tumorigenesis mediated by an antigen receptor. Proc Natl Acad Sci USA 89 (1992) 8482-8486
9. Gallagher R.P., Spinelli J.J., Elwood J.M., and Skippen D.H. Allergies and agricultural exposure as risk factors for multiple myeloma. Br J Cancer 48 (1983) 853-857
10. Lewis D.R., Pottern L.M., Brown L.M., et al. Multiple myeloma among blacks and whites in the United States: the role of chronic antigenic stimulation. Cancer Causes Control 5 (1994) 529-539
11. Friedman D.F., Cho E.A., Goldman J., et al. The role of clonal selection in the pathogenesis of an autoreactive human B cell lymphoma. J Exp Med 174 (1991) 525-537
12. Seligmann M., and Brouet J.C. Antibody activity of human myeloma globulins. Semin Hematol 10 (1973) 163-177
13. Colwell N.S., Tollefsen D.M., and Blinder M.A. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 97 (1997) 219-226
14. Konrad R.J., Kricka L.J., Goodman D.B., Goldman J., and Silberstein L.E. Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N Engl J Med 328 (1993) 1817-1819
15. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92 (1995) 11810-11813
16. Xie X., Schmits R., Renner C., Preuss D., Kubuschok B., and Pfreundschuh M. Systematic search and molecular characterization of the antigenic targets of myeloma immunoglobulins: a monoclonal IgA from a female patient targeting sperm-specific cylicin II. Cancer Immun 1 (2001) 11
17. Preuss K.D., Held G., Kubuschok B., et al. Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS. Int J Cancer 121 (2007) 459-461
18. Preuss K.D., Pfreundschuh M., Ahlgrimm M., et al. A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. Int J Cancer 125 (2009) 656-661
19. Wang Y., and Morrow J.S. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem 275 (2000) 8062-8071
20. Cao W., Zhang B., Liu Y., et al. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 128 (2007) 430-436
21. Cao W.F., Zhang L.Y., Liu M.B., Tang P.Z., Liu Z.H., and Sun B.C. Prognostic significance of stomatin-like protein 2 overexpression in laryngeal squamous cell carcinoma: clinical, histologic, and immunohistochemistry analyses with tissue microarray. Hum Pathol 38 (2007) 747-752
22. Cui Z., Zhang L., Hua Z., Cao W., Feng W., and Liu Z. Stomatin-like protein 2 is overexpressed and related to cell growth in human endometrial adenocarcinoma. Oncol Rep 17 (2007) 829-833
23. Kirchhof M.G., Chau L.A., Lemke C.D., et al. Modulation of T cell activation by stomatin-like protein 2. J Immunol 181 (2008) 1927-1936
24. Tondera D., Grandemange S., Jourdain A., et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J 28 (2009) 1589-1600
25. Kritzman J., Kunkel H.G., McCarthy J., and Mellors R.C. Studies of a Waldenstrom-type macroglobulin with rheumatoid factor properties. J Lab Clin Med 57 (1961) 905-917
26. Braun P.E., Frail D.E., and Latov N. Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem 39 (1982) 1261-1265
27. Trimarchi F., Benvenga S., Fenzi G., Mariotti S., and Consolo F. Immunoglobulin binding of thyroid hormones in a case of Waldenstrom's macroglobulinemia. J Clin Endocrinol Metab 54 (1982) 1045-1050
28. Dighiero G., Guilbert B., Fermand J.P., Lymberi P., Danon F., and Avrameas S. Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood 62 (1983) 264-270
29. Mills L.E., Brettman L.R., Jentoft J.E., Viner E.D., and Bernier G.M. Crystallocryoglobulinemia resulting from human monoclonal antibodies to albumin. Ann Intern Med 99 (1983) 601-604
30. Kilgore L.L., Patterson B.W., Parenti D.M., and Fisher W.R. Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest 76 (1985) 225-232
31. Redmon B., Pyzdrowski K.L., Elson M.K., Kay N.E., Dalmasso A.P., and Nuttall F.Q. Hypoglycemia due to an insulin-binding monoclonal antibody in multiple myeloma. N Engl J Med 326 (1992) 994-998
32. Landgren O., Linet M.S., McMaster M.L., Gridley G., Hemminki K., and Goldin L.R. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118 (2006) 3095-3098
33. Landgren O., Zhang Y., Zahm S.H., Inskip P., Zheng T., and Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15 (2006) 2342-2347
34. Goldin L.R., and Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 124 (2009) 1497-1502
35. Kohler M., Daus H., Kohler C., Schlimmer P., Wernert N., and Scheurlen P.G. Lymphocytic plasmocytoid lymphoma with a three-banded gammopathy: reactivity of one of these paraproteins with cytomegalovirus. Blut 54 (1987) 25-32
36. Sompuram S.R., Bastas G., Vani K., and Bogen S.A. Accurate identification of paraprotein antigen targets by epitope reconstruction. Blood 111 (2008) 302-308
37. Shoenfeld Y., Berliner S., Shaklai M., Gallant L.A., and Pinkhas J. Familial multiple myeloma. A review of thirty-seven families. Postgrad Med J 58 (1982) 12-16
38. Eriksson M., and Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 3 (1992) 63-67
39. Lynch H.T., Watson P., Tarantolo S., et al. Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23 (2005) 685-693
40. Agnelli L., Mosca L., Fabris S., et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 48 (2009) 603-614
41. Hosgood III H.D., Baris D., Zhang Y., et al. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res (2009) 10.1016/j.leukres.2009.03.013 published online April 10.
42. Jenner M.W., Leone P.E., Walker B.A., et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110 (2007) 3291-3300
43. Alexander D.D., Mink P.J., Adami H.O., et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120 suppl 12 (2007) 40-61
44. Kristinsson S.Y., Bjorkholm M., Goldin L.R., McMaster M.L., Turesson I., and Landgren O. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 112 (2008) 3052-3056
45. Mohammed F., Cobbold M., Zarling A.L., et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat Immunol 9 (2008) 1236-1243
46. Meyer V.S., Drews O., Gunder M., Hennenlotter J., Rammensee H.G., and Stevanovic S. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J Proteome Res 8 (2009) 3666-3674